OncoMatch/Clinical Trials/NCT02691923
Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker
Is NCT02691923 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Fluorescein and Fluorescein + ALA for brain cancer.
Treatment: Fluorescein · Fluorescein + ALA — This clinical research will evaluate the diagnostic potential of fluorescein as visualized through an operating microscope relative to 1) contrast enhancement on co-registered preoperative MR scans, 2) intraoperative ALA-induced PpIX fluorescence and 3) gold-standard histology obtained from biopsy sampling during the procedure. Subjects will include those people with operable brain tumor with first-time presumed pre-surgical diagnosis of high-grade glioma or low-grade glioma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Lab requirements
Kidney function
Serum creatinine ≤ 180µmol/L (2.04 mg/dL) within 30 days prior to surgery.
Liver function
No history of liver disease within the last 12 months. AST, ALT, ALP or bilirubin levels must be ≤ 2.5 times the normal limit within 30 days prior to surgery.
History of liver disease within the last 12 months [excluded]. Elevated LFTs (AST, ALT, ALP or bilirubin levels greater than 2.5 times the normal limit) from laboratory tests conducted within 30 days prior to surgery [excluded]. Serum creatinine in excess of 180µmol/L (2.04 md/dL) within 30 days prior to surgery [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sally B Mansur · Lebanon, New Hampshire
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify